FLT3 and acute myeloid leukemia: Meanwhile, a recent study demonstrated that FES activity was required for Flt3 function in acute myelogenous leukemia (AML), and in fact, dual inhibition of both Flt3 and FES might provide a therapeutic advantage for the treatment (Weir et al. 2017).